Uptake of Outpatient Monoclonal Antibody Treatments for COVID-19 in the United States: a Cross-Sectional Analysis
J Gen Intern Med
.
2021 Dec;36(12):3922-3924.
doi: 10.1007/s11606-021-07109-5.
Epub 2021 Sep 8.
Authors
Timothy S Anderson
1
2
3
,
Ashley L O'Donoghue
4
,
Tenzin Dechen
4
,
Oren Mechanic
5
,
Jennifer P Stevens
4
6
7
Affiliations
1
Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. tsander1@bidmc.harvard.edu.
2
Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA, USA. tsander1@bidmc.harvard.edu.
3
Harvard Medical School, Boston, MA, USA. tsander1@bidmc.harvard.edu.
4
Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA, USA.
5
Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, MA, USA.
6
Harvard Medical School, Boston, MA, USA.
7
Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
PMID:
34495464
PMCID:
PMC8425019
DOI:
10.1007/s11606-021-07109-5
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Antibodies, Monoclonal
COVID-19*
Cross-Sectional Studies
Humans
Outpatients
SARS-CoV-2
United States
Substances
Antibodies, Monoclonal